

**TRN005:
Targeted
Eosinophil
Depleting
Therapy (EMR1)**

Humaneered™ eosinophil-specific target:
EMR1

Highly selective for human eosinophils

Potent Antibody-Dependent Cellular
Cytotoxicity (ADCC) activity

Selective eosinophil clearance demonstrated
in primates

Work conducted by NIH

**Multiple
Opportunities:
Orphan
Conditions Allow
Fast, Inexpensive
Market Entry
Point**

Orphan

- Churg-Strauss Syndrome
- Hypereosinophilic Syndrome
- Eosinophilic Leukemia

GI

- Inflammatory Bowel Disease
- Eosinophilic esophagitis

Multiple Respiratory/Nasal